| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Ryoichi Yano | Q73393199 |
| P2093 | author name string | Kyohei Watanabe | |
| Toshiaki Nakamura | |||
| Yuichiro Kayano | |||
| Hitoshi Tsukamoto | |||
| Mikio Masada | |||
| Nobuyuki Goto | |||
| Aya Konno | |||
| Hiroaki Ohnaka | |||
| P2860 | cites work | Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics | Q27851471 |
| Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells | Q28275578 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 | ||
| Docetaxel in patients with anthracycline-resistant advanced breast cancer | Q31814581 | ||
| Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group | Q33328841 | ||
| Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan | Q33329495 | ||
| A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer | Q33335910 | ||
| Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial | Q33364662 | ||
| Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel | Q33369267 | ||
| Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer | Q33371032 | ||
| Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. | Q54156953 | ||
| Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study | Q57216455 | ||
| Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer | Q57580011 | ||
| A Phase II study of docetaxel in patients with liver metastases from breast cancer | Q59289112 | ||
| Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue | Q59305087 | ||
| Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy | Q70790891 | ||
| Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study | Q71059826 | ||
| A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC | Q71455446 | ||
| Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix | Q71579228 | ||
| Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials group | Q72008072 | ||
| [Late phase II trial of RP56976 (Docetaxel) in patients with non-small-cell lung cancer] | Q72420345 | ||
| Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer | Q72516643 | ||
| Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer | Q72679565 | ||
| Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer | Q72679569 | ||
| Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma | Q72690159 | ||
| [An early phase II clinical study of RP56976 (docetaxel) in patients with breast cancer] | Q72765218 | ||
| [Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer. Docetaxel Cooperative Study Group for Lung Cancer] | Q72854278 | ||
| A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2 | Q73287848 | ||
| A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study | Q73505906 | ||
| Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice | Q74341457 | ||
| Phase II trial of docetaxel for cholangiocarcinoma | Q74455186 | ||
| Phase II trial of docetaxel (Taxotere) for untreated advanced colorectal carcinoma | Q74651416 | ||
| [A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B)] | Q74654940 | ||
| [Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)] | Q77495599 | ||
| Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience | Q77849006 | ||
| Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial | Q78103596 | ||
| A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy. Hellenic Cooperative Interhospital Group in Oncology | Q78147266 | ||
| [Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer] | Q78165160 | ||
| Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer | Q79317427 | ||
| Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904) | Q80025942 | ||
| A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy | Q80371789 | ||
| A clinical study of docetaxel with or without 5'DFUR as a second-line chemotherapy for advanced gastric cancer | Q80731639 | ||
| Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial | Q80978841 | ||
| Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice | Q81803899 | ||
| Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer | Q82892839 | ||
| A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy | Q83143070 | ||
| Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma | Q83215418 | ||
| Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer | Q33371137 | ||
| Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. | Q33384024 | ||
| Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group | Q33490888 | ||
| Phase II clinical study of RP56976 (docetaxel) in patients with carcinoma ovarii or carcinoma colli uteri | Q33491044 | ||
| Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma | Q33499366 | ||
| A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma | Q33961394 | ||
| Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy | Q34547495 | ||
| Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer | Q34596877 | ||
| Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group | Q36080032 | ||
| Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study | Q36080058 | ||
| Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients | Q36115695 | ||
| A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer | Q36134486 | ||
| A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer | Q36135843 | ||
| Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. | Q36614629 | ||
| Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. | Q36615520 | ||
| A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment | Q36615741 | ||
| Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer | Q36667452 | ||
| Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure | Q36692486 | ||
| A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. | Q36695252 | ||
| Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans | Q36800169 | ||
| A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204) | Q36882714 | ||
| Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy | Q37414536 | ||
| Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer | Q37496425 | ||
| A phase II study of higher dose docetaxel in androgen-independent prostate cancer | Q39347724 | ||
| A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer | Q40192736 | ||
| A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. | Q40226887 | ||
| Chemoprotection effect of retroviral vector encoding multidrug resistance 1 gene to allow intensified chemotherapy in vivo | Q40351935 | ||
| Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan | Q40421598 | ||
| Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients | Q40534374 | ||
| Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study | Q40569006 | ||
| Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy | Q40579509 | ||
| Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer | Q40619970 | ||
| Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy | Q40667276 | ||
| Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. | Q40667282 | ||
| Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum | Q40668541 | ||
| Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer | Q40676178 | ||
| Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer | Q40677493 | ||
| Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer | Q40687767 | ||
| Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer | Q40694116 | ||
| Late phase II clinical study of RP56976 (docetaxel) in patients with non-small cell lung cancer | Q40694124 | ||
| Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer | Q40694207 | ||
| An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract | Q40695268 | ||
| Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer | Q40994604 | ||
| Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B. | Q41615198 | ||
| Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial | Q41712544 | ||
| A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. | Q42281832 | ||
| A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer | Q42538900 | ||
| Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer | Q42631933 | ||
| Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthra | Q43290572 | ||
| First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study | Q43750756 | ||
| Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial | Q43791704 | ||
| Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer | Q43850218 | ||
| Malignant pleural mesothelioma: a phase II trial with docetaxel | Q43983629 | ||
| Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus | Q43988072 | ||
| Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial | Q44153194 | ||
| A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study | Q44315213 | ||
| Docetaxel as Neoadjuvant Chemotherapy in Patients With Advanced Cervical Carcinoma | Q44607739 | ||
| Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). | Q44687159 | ||
| Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer | Q44695845 | ||
| A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer | Q44902236 | ||
| Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial | Q44958693 | ||
| A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer | Q45023413 | ||
| A phase II study of docetaxel in patients with metastatic carcinoid tumors | Q45114038 | ||
| A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen | Q45125373 | ||
| Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). | Q45187274 | ||
| A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer | Q45190962 | ||
| Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol | Q45229159 | ||
| Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802). | Q46103036 | ||
| Docetaxel for metastatic breast cancer: two consecutive phase II trials. | Q46133900 | ||
| Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). | Q46150918 | ||
| Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. | Q46232500 | ||
| A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer | Q46487403 | ||
| Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. | Q46591845 | ||
| Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer | Q46658468 | ||
| Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer | Q46733372 | ||
| Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer | Q46816720 | ||
| Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial | Q46863365 | ||
| Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer | Q46965899 | ||
| Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. | Q52250579 | ||
| Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. | Q53196556 | ||
| Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. | Q53521886 | ||
| A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). | Q53527972 | ||
| Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. | Q54027653 | ||
| Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. | Q54045033 | ||
| Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. | Q54071888 | ||
| P433 | issue | 1 | |
| P921 | main subject | phase II clinical trial | Q42824440 |
| P304 | page(s) | 96-104 | |
| P577 | publication date | 2011-11-18 | |
| P1433 | published in | International Journal of Clinical Oncology | Q15758148 |
| P1476 | title | Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials | |
| P478 | volume | 18 |
| Q53673558 | A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA). |
| Q88983830 | A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx |
| Q51425302 | A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer. |
| Q49650663 | Chemo-selection with docetaxel, cisplatin and 5-fluorouracil (TPF) regimen followed by radiation therapy or surgery for pharyngeal and laryngeal carcinoma |
| Q88651638 | Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients |
| Q34511068 | Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis |
| Q30847864 | Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program |
| Q47926809 | Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study |
| Q33584160 | Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results |
| Q64232018 | Gemcitabine Plus Cisplatin Split Gemcitabine Plus Carboplatin for Advanced Urothelial Cancer With Cisplatin-unfit Renal Function |
| Q92075168 | Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan |
| Q38414294 | Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer |
| Q47375559 | Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease |
| Q54963459 | Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis. |
| Q35674153 | Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose |
| Q39317847 | Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer |
| Q64948519 | Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series. |
| Q40100374 | Score of liver ultrasonography predicts treatment-related severe neutropenia and neutropenic fever in induction chemotherapy with docetaxel for locally advanced head and neck cancer patients with normal serum transamines. |
Search more.